Harry A. Peters

Universitätsmedizin Göttingen — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.7kcitations44works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protease and Inhibitor Mechanisms(16), Cell Adhesion Molecules Research(7), Estrogen and related hormone effects(6), Blood Coagulation and Thrombosis Mechanisms(4), S100 Proteins and Annexins(4)

Publications44 total

Dendritische Zelltherapie bei metastasiertem Mammakarzinom
Geburtshilfe und Frauenheilkunde·2008
Dendritic cell therapy in glioblastoma multiforme
Journal of Clinical Oncology·2007· 3 cited
Gender effects on cardiovascular and renal outcome in mild uremia
UEA Digital Repository (University of East Anglia)·2007
Implementation and Performance Study of a New NAT/Firewall Signaling Protocol
2006· 6 cited
The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer
Clinical Cancer Research·2004· 53 cited
Development of an ELISA for Measurement of BCAR1 Protein in Human Breast Cancer Tissue
Clinical Chemistry·2004· 12 citedOpen Access
Urokinase-Type Plasminogen Activator System in Breast Cancer
Cancer Research·2004· 68 cited
Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer
Clinical Cancer Research·2004· 123 cited
Tissue inhibitor of metalloproteinases-1 (TIMP-1) and prognosis in primary breast cancer: an EORTC—RBG collaborative validation study including 2984 patients
European Journal of Cancer Supplements·2004
22 Total tumour tissue levels of tissue inhibitor of metalloproteinases-1 as a prognostic marker in breast cancer: an EORTC validation study of 2984 patients
European Journal of Cancer Supplements·2003
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
PubMed·2003· 74 cited
Natural Surface Phenomena and the Impact of Corrosion Inducing Salts
2002· 1 cited
Clinical relevance of biologic factors in male breast cancer
Breast Cancer Research and Treatment·2001· 61 cited
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
PubMed·2001· 300 cited
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer
Annals of Oncology·2000· 52 citedOpen Access
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
PubMed·2000· 429 cited
Tumour growth pattern and degree of thymidine phosphorylase expression are strongly related to metastasis risk in Dukes B colorectal cancer.
Annals of Oncology·2000
Breast-Conserving Therapy: Proteases as Risk Factors in Relation to Survival After Local Relapse
Journal of Clinical Oncology·1999· 23 cited
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
British Journal of Cancer·1999· 42 citedOpen Access
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
British Journal of Cancer·1999· 40 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

John A. Foekens(23), Maxime P. Look(13), J.G.M. Klijn(12), Marion E. Meijer‐van Gelder(10), Jan G.M. Klijn(10), Henk Portengen(8), Fred C.G.J. Sweep(6), W L van Putten(6), J.G.M. Klijn(5), M. Bontenbal(5), Anieta M. Sieuwerts(5), Manfred Schmitt(4), Nils Brünner(4), Wim L.J. van Putten(4), Nicolaï Grebenchtchikov(4), Anneke Geurts‐Moespot(4), Buddy Setyono-Han(4), J.A. Foekens(4), Michael D. Kramer(3), F. Jänicke(3)